Clinical Trials
6
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:5
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 2
1 (16.7%)Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: LioCyx-M, HBV antigen-specific TCR-redirected T cells
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06961617
- Locations
- 🇨🇳
Gaobo Boren Hospital, Beijing, China
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular CarcinomaLiver Cancer, AdultLiver Cell Carcinoma
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT05195294
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT04745403
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Phase 1
Withdrawn
- Conditions
- Recurrent Hepatocellular Carcinoma
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Registration Number
- NCT03634683
- Locations
- 🇨🇳
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangzhou, China
🇨🇳The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangzhou, China
🇸🇬National University Hospital, Singapore, Singapore
A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation
Phase 1
- Conditions
- Recurrent Hepatocellular Carcinoma
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Lion TCR Pte. Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT02719782
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- Next
News
No news found